1. Juan CosínaJ., Díezb J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (4): 507-13.
2. National guidelines of SSHF, RCS and RSMST for diagnosis and treatment of chronic heart failure (fourth revision). Available at: http://upload.ossn.ru/medialibrary/574/574223742687ee0c61b85db0115308be/SSHF_Guidelines_rev.4.0.3.pdf. Accessed by 10/10/2014. Russian (Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). До-ступно на: http://upload.ossn.ru/medialibrary/574/574223742687ee0c61b85db0115308be/SSHF_Guidelines_rev.4.0.3.pdf. Проверено 10.10.2014).
3. Rector Th., Cohn J. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-mind, placebo-controlled trial of pimobendan. Am Heart J 1992; 124 (4): 1017-24.
4. Belenkov YN, Mareev VY On the classification of congestive heart failure at the turn of the century. Serdechnaya Nedostatochnost' 2000; 2 (3): 88-90. Russian (Беленков Ю.Н., Мареев В.Ю. К вопросу о клас-сификации хронической сердечной недостаточности на рубеже веков. Сердечная Недостаточ-ность 2000; 2(3): 88-90).
5. World Medical Association. World Medical Association Declaration of Helsinki. 52nd WMA General Assembly; 2004. Available at: http://www.wma.net/e/policy/pdf/17c.pdf. Accessed by 10.10.2014.
6. Kobalava ZD, Villevalde SV, Moiseyev VS. The value of different methods of evaluation of renal function to stratify cardiovascular risk. Kardiologiya 2007; 47 (12): 74-80. Russian (Кобалава Ж.Д., Вил-левальде С.В., Моисеев В.С. Значение различных методов оценки функционального состояния почек для стратификации сердечно-сосудистого риска. Кардиология 2007; 47(12): 74-80).
7. Lapich SN, Chubenko AV, Babich PNю Statistical methods in biomedical research using Excel. Kiev: Morion; 2001. Russian (Лапич С.Н., Чубенко А.В., Бабич П.Н. Статистические методы в медико-био-логических исследованиях с использованием Excel. Киев: Морион; 2001).
8. Friedel H., Buckley M. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs 1991; 41(1): 81-103.
9. Kim E.J., Lee M.G. Pharmacokinetics and pharmacodynamics of intravenous torasemide in mutant Nagase analbuminetic rats. Biopharm. Drug Dispos 2003; 24(1): 27-35.
10. Hall WD. Abnormalities of kidney function as a cause and a consequence of cardiovascular disease. Am J Med Sci 1999; 317: 176-82.
11. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Co Cardiol 1992; 20: 248-54.
12. Carrie BJ, Hilberman M, Schroeder JS, Myers BD. Albuminuria and the permselective properties of the glomerulus in cardiac failure. Kidney Int 1980; 17: 507–14.
13. Chow KM, Szeto CC, Wong TY et al. Risk factors for thiazide-induced hyponatraemia. QJM 2003; 96 (12): 911-7.
14. Kittleson M, Hurwitz S, Shah MR et al. Development of circulatory-renal limitations to angiotensinconverting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am CollCardiol 2003; 41 (11): 2029-35.
15. Mukhin NA, Fomin VV, Moiseev SV, Khamkhoev MS. Chronic heart failure and kidney disease: prospects for treatment. Consilium Medicum 2008; 9: 69-74. Russian (Мухин Н.А., Фомин В.В., Моисеев С.В., Хамхоева М.С. Хроническая сердечная недостаточность и поражение почек: перспекти-вы лечения. ConsiliumMedicum 2008; 9: 69-74).
16. Noe L.L., Vreeland M.G., Pezzella S.M., Trotter J.P. A pharmaeconomical assessment of torasemide and furosemide in the treatment of patients with congestive heart failure. ClinTher 1999; 21(5): 854-6.
17. Muller K, Gamba G, Jaquet F et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV – efficacy and quality of life. Eur J Heart Fail 2003; 5 (6): 793–801.
18. Puschett J.B. Pharmacological classification and renal actions of diuretic. Cardiology 1994; 84 Suppl 2: 4-13.
19. Uchida T., Yamanaga K., Kido H. Diuretic and vasodilating actions of torasemide. Cardiology 1994; 84 (Suppl 3): 14-7.
20. Uchida T., Yamanaga K., Nishikawa M. et al. Antialdosteronic effects of torasemide. Eur J Pharm 1991; 205: 145-50.